Page 52 - TD-4-3

Tumor Discovery HRD genomic alterations in Chinese NSCLC

landscapes. Genes (Basel). 2024;15(5):577. The multifaceted role of the STING in the TME and
doi: 10.3390/genes15050577 new prospects in cancer therapies. Cell Commun Signal.
2025;23(1):171.
35. Tsilingiri K, Chalari A, Christopoulou G, et al. Genomic
scarring score predicts the response to PARP inhibitors in doi: 10.1186/s12964-025-02169-0
non-small cell lung cancer. NPJ Precis Oncol. 2024;8(1):291. 39. Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line
doi: 10.1038/s41698-024-00777-6 nivolumab plus ipilimumab combined with two cycles of
chemotherapy in patients with non-small-cell lung cancer
36. Wang Y, Ma Y, He L, et al. Clinical and molecular significance (CheckMate 9LA): An international, randomised, open-
of homologous recombination deficiency positive non- label, phase 3 trial [published correction appears in Lancet
small cell lung cancer in Chinese population: An integrated
genomic and transcriptional analysis. Chin J Cancer Res. Oncol. 2021;22(3):e92.
2024;36(3):282-297. doi: 10.1016/S1470-2045(21)00082-6.]. Lancet Oncol.
doi: 10.21147/j.issn.1000-9604.2024.03.05 2021;22(2):198-211.
37. Bie F, Tian H, Sun N, et al. Comprehensive analysis of PD-L1 doi: 10.1016/S1470-2045(20)30641-0
expression, tumor-infiltrating lymphocytes, and tumor 40. Domchek SM, Postel-Vinay S, Im SA, et al. Olaparib and
microenvironment in LUAD: Differences between Asians durvalumab in patients with germline BRCA-mutated
and Caucasians. Clin Epigenetics. 2021;13(1):229. metastatic breast cancer (MEDIOLA): An open-label,
doi: 10.1186/s13148-021-01221-3 multicentre, phase 1/2, basket study. Lancet Oncol.
2020;21(9):1155-1164.
38. Wang S, Qin L, Liu F, Zhang Z. Unveiling the crossroads of
STING signaling pathway and metabolic reprogramming: doi: 10.1016/S1470-2045(20)30324-7

Volume 4 Issue 3 (2025) 44 doi: 10.36922/TD025180032